Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Non-small Cell Lung Cancer × osimertinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 152 Lung Neoplasms 48 Neoplasms 13 NSCLC 11 Neoplasm Metastasis 10 Brain Neoplasms 10 Carcinoma 8 Meningeal Carcinomatosis 6 Bronchial Neoplasms 5 Thoracic Neoplasms 4 Colorectal Neoplasms 4 Respiratory Tract Neoplasms 3 Respiratory Tract Diseases 3 Neoplasms by Site 3 Lung Diseases 3 Adenocarcinoma of Lung 3 Adenocarcinoma 3 Squamous Cell Carcinoma of Head and Neck 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Noonan Syndrome 2 Non Small Cell Lung Cancer Metastatic 2 Neoplasms, Nerve Tissue 2 Neoplasms by Histologic Type 2 Head and Neck Neoplasms 2 Carcinoma, Squamous Cell 2 Carcinoma, Bronchogenic 2 Breast Neoplasms 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1

Interventions

Docetaxel 4 pembrolizumab 3 Pemetrexed 3 Nivolumab 2 Cisplatin 2 Carboplatin 2 tislelizumab 1 rofecoxib 1 paclitaxel poliglumex 1 osimertinib 1 nazartinib 1 lenvatinib 1 cemiplimab 1 aumolertinib 1 atezolizumab 1 anlotinib 1 aflutinib 1 abivertinib 1 Rosuvastatin Calcium 1 Radiosurgery 1 RO5126766 1 Platinum Compounds 1 Midazolam 1 Gemcitabine 1 Gefitinib 1 Food 1 Esomeprazole 1 Drug Therapy 1 Dabigatran 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05489731 2023-06-15

VIC-1911

Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd.

Phase 1 Unknown

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡